Mankind Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 19/05/2026 ,inter alia, to consider and approve standalone and consolidated ....
MANKIND · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Mankind Pharma has informed exchanges that its Board meeting is scheduled for May 19, 2026. The meeting will consider and approve the standalone and consolidated audited financial results for Q4 and FY ended March 31, 2026. Additionally, the Board will review the realignment of security cover for existing Non-Convertible Debentures (NCDs), following the redemption of an NCD tranche worth ₹1,250 Crores on April 16, 2026. Two NCD issues remain outstanding: one for ₹1,250 Crores maturing October 16, 2026, and another for ₹250 Crores maturing November 16, 2027. The trading window for insider trading prevention will remain closed until May 21, 2026.
The filing is routine and indicates the company is on track to release its annual results. The NCD redemption of ₹1,250 Crores represents a significant debt reduction, which could be positive for the company's balance sheet. No material concerns are raised for shareholders at this stage.